YocumDEKlippelJHWilderRLGerberNLAustinHAWahlSM. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. Ann Intern Med1988; 109: 863–9.
2.
KremerJM. Severe rheumatoid arthritis: Current options in drug therapy. Geriatrics1990; 45: 43–8.
3.
DougadosMAwadaHAmorB. Cyclosporin in rheumatoid arthritis: A double blind, placebo controlled study in 52 patients. Ann Rheum Dis1988; 47: 127–33.
4.
DougadosMDuchesneLAwadaHAmorB. Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis1989; 48: 550–6.
5.
WeinblattMECoblynJSFraserPAAndersonRJSpraggJTrenthamDE. Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum1987; 30: 11–7.
6.
Van RijthovenAWAMDijkmansBACTheGoei HSHermansJMontnor-BeckersZLMBJacobsPCJ. Cyclosporin treatment for rheumatoid arthritis: A placebo controlled, double blind, multicentre study. Ann Rheum Dis1986; 45: 726–31.
7.
TugwellPBombardierCGentMBennettKJBensenWGCaretteS. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet1990; 335: 1051–5.
8.
FørreØBjerkhoelFSalvesenCFBergKJRugstadHESaelidG. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: A preliminary report. Arthritis Rheum1987; 30: 88–92.
9.
BergKJFørreØDjøselandOMikkelsenMNarverudJRugstadHE. Renal side effects of high and low cyclosporin A doses in patients with rheumatoid arthritis. Clin Nephrol1989; 31: 232–8.
10.
SchenkerSHoyumpaAM. Pathophysiology of hepatic encephalopathy. Hosp Pract1984; 19: 99–121.
11.
ConnHOLeevyCMVlahcevicZRRodgersJBMaddreyWCSeeffL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: A double blind controlled trial. Gastroenterology1977; 72: 573–83.
12.
OrlandiFFreddaraUCandelaresiMTMorettiniACorazzaGRSimoneAD. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: A randomized clinical study. Dig Dis Sci1981; 26: 498–506.
13.
HorstDGraceNDConnHOSchiffESchenkerSViteriA. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: A randomized controlled trial. Hepatology1984; 4: 279–87.
14.
HindfeltBPlumFDuffyTE. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest1977; 59: 386–96.
15.
JamesJHZiparoVJeffssonBFischerJE. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: A unified theory of portal-systemic encephalopathy. Lancet1979; 2: 772–5.
16.
FraserCLArieffAI. Hepatic encephalopathy. N Engl J Med1985; 313: 865–73.
17.
SchaferDFJonesEA. Potential neural mechanisms in the pathogenesis of hepatic encephalopathy. Prog Liver Dis1982; 7: 615–27.
18.
LivingstoneASPotvinMGoreskyCAFinlaysonMHHincheyEJ. Changes in the blood-brain barrier in hepatic coma after hepatectomy in the rat. Gastroenterology1977; 73: 697–704.
19.
BasileASOstrowskiNLGammalSHJonesEASkolnickP. The involvement of the benzodiazepine receptor in hepatic encephalopathy: Evidence for the presence of a benzodiazepine receptor ligand. Adv Biochem Psychopharmacol1990; 46: 189–200.
20.
SchaferDFFowlerJMJonesEA. Colonic bacteria: A source of gamma aminobutyric acid in blood. Proc Soc Exp Biol Med1981; 167: 301–3.
21.
MunikGYWinderABurgessEDSarjeantEJ. Serum gamma-aminobutyric acid (GABA) levels in patients with hepatic encephalopathy. Hepatogastroenterology1985; 32: 171–4.
22.
FerenciPSchaferDFKleinbergerGHoofnagleJH. Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease. Lancet1983; 2: 811–4.
23.
LevyLJLosowskyMS. Plasma gamma aminobutyric acid concentrations provide evidence of different mechanisms in the pathogenesis of hepatic encephalopathy in acute and chronic liver disease. Hepatogastroenterology1989; 36: 494–8.
24.
WahlMUnterbergABaethmannASchillingL. Mediators of blood-brain barrier dysfunction and formation of vasogenic brain edema. J Cereb Blood Flow Metab1988; 8: 621–34.
25.
BassettMLMullenKDSkolnickPJonesEA. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABA-A benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology1987; 93: 1069–77.
26.
SchaferDFFowlerJMMunsonPJThakurAKWaggonerJGJonesEA. Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Lab Clin Med1983; 102: 870–80.
27.
BasileASGammalSHMullenKDJonesEASkolnickP. Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. J Neurosci1988; 8: 2414–21.
28.
GammalSHBasileASGellerDSkolnickPJonesEA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligand. Hepatology1990; 11: 371–8.
29.
MyslobodskyMS. Gamma-aminobutyric acid (GABA) and hepatic encephalopathy: Testing the validity of electroencephalographic evidence of the GABA hypothesis. Hepatogastroenterology1987; 34: 58–64.
30.
BasileASHughesRDHarrisonPMMurataYPannellLJonesEA. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med1991; 325: 473–8.
31.
MeierRGyrK. Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: A pilot study. Eur J Anaesthesiol1988; 2: 139–46.
32.
GrimmGKatzenschlagerRHolznerFFerenciPSchneeweissBLaggnerA. Effect of flumazenil in hepatic encephalopathy. Eur J Anaesthesiol1988; 2: 147–9.
33.
GrimmGKatzenschlagerRSchneeweissBLenzKFerenciPMadlC. Improvement of hepatic encephalopathy treated with flumazenil. Lancet1988; 2: 1392–4.
34.
Pomier-LayrarguesGGigu'ereJFLovoieJWillemsBButterworthRF. Pharmacokinetics of benzodiazepine antagonist Ro 15–1788 in cirrhotic patients with moderate or severe liver dysfunction. Hepatology1989; 10: 969–72.
35.
BanskyGMeierPJRiedererEWalserHZieglerWHSchmidM. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology1989; 97: 744–50.
36.
MullenKDSzauterKMKaminsky-RussK. “Endogenous” benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet1990; 336: 81–3.
37.
RothsteinJDMcKhannGGuarneriPBarbacciaMLGuidottaACostaE. Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy. Ann Neurol1989; 26: 57–62.
